The ENCIRCLE Trial

NAACTIVE_NOT_RECRUITING

This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

Study details:

This is a prospective single-arm, multicenter study.

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  1. 18 years of age or older
  2. MR ≥ 3+
  3. NYHA functional class ≥ II
  4. Per the Heart Team, commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomic or technical considerations.
  5. Subject's heart failure management has been optimized based on subject characteristics and applicable guidelines, and stable for at least 30 days prior to enrollment.
  6. The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion criteria

  1. Mitral/cardiac anatomy that would preclude appropriate delivery and deployment of the SAPIEN M3 dock or valve
  2. Inappropriate anatomy for femoral introduction and delivery of the SAPIEN M3 dock and valve
  3. Presence of any device that will contact or interfere with the SAPIEN M3 System during delivery or after implantation
  4. Left ventricular ejection fraction <25%
  5. Severe right ventricular dysfunction
  6. Need for aortic, tricuspid or pulmonic valve intervention within the next 12 months
  7. History of heart transplant
  8. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
  9. Active bacterial endocarditis within 180 days of the procedure
  10. Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure
  11. Myocardial infarction within 30 days of the procedure
  12. Clinically significant untreated coronary artery disease requiring revascularization
  13. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of the procedure
  14. Stroke or transient ischemic attack within 90 days of the procedure
  15. Irreversible, severe pulmonary hypertension
  16. Chronic obstructive pulmonary disease requiring home oxygen therapy or chronic outpatient oral steroid use
  17. Renal insufficiency or receiving renal replacement therapy
  18. Liver disease
  19. Planned surgery within the next 12 months
  20. Inability to tolerate or a medical condition precluding treatment with antithrombotic therapy, including heparin administration during the procedure
  21. Active infection requiring current antibiotic therapy
  22. Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
  23. Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or hypercoagulable states
  24. Refusal of blood products
  25. Female who is pregnant or lactating
  26. Estimated life expectancy <12 months due to non-cardiac conditions
  27. Participating in another investigational drug or device study that has not reached its primary endpoint
  28. Subject considered to be part of a vulnerable population

Eligibility

Age eligible for study : NA

Healthy volunteers accepted : No

Gender eligible for study: ALL

Things to know

Study dates

Study start:

Primary completion:

Study completion finish:

study type

Study type

TREATMENT

phase

Phase

    NA

trial

Study ID

NCT04153292

Intervention or treatment

DEVICE: SAPIEN M3 valve and dock

Conditions

  • Mitral Regurgitation
  • Mitral Valve Insufficiency
  • Condition: Mitral Regurgitation, Mitral Valve Insufficiency

  • DEVICE: SAPIEN M3 valve and dock

  • Chermside, Queensland, Australia and more

  • Sponsor: Edwards Lifesciences

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial?

If you're a clinic or sponsor, you can claim this study

Research sites nearby

Closest Location:

The Prince Charles Hospital

Select from list below to view details:

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Royal Prince Alfred Hospital

    Camperdown, Australia

Loading map...

Who is running the clinical trial?

EL

Edwards Lifesciences

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: TMVR - Main Cohort
  • Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).
Device: SAPIEN M3 valve and dock
    EXPERIMENTAL: TMVR - Failed TEER Registry
    • Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.
    Device: SAPIEN M3 valve and dock
      EXPERIMENTAL: TMVR - MAC Registry
      • Subjects with mitral annular calcification (MAC) will have TMVR.
      Device: SAPIEN M3 valve and dock

        What is the study measuring?

        Primary Outcome

        MeasureDescriptionTime Frame
        Non-hierarchical composite of death and heart failure rehospitalizationNumber of subjects with death and/or heart failure rehospitalization1 year

        Secondary Outcome

        MeasureDescriptionTime Frame
        Improvement in NYHA functional class compared to baselineNew York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.1 year
        Improvement in KCCQ Overall Score compared to baselineThe Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.1 year
        Improvement in MR compared to baselineNumber of subjects with improved MR compared to baseline1 year
        Decrease in LVEDVi compared to baselineNumber of subjects with decreased left ventricular end-diastolic volume index (LVEDVi) compared to baseline1 year
        Are you running this trial?If you're a clinic or sponsor, you can claim this study.

        References

        Clinical Trials Gov: The ENCIRCLE Trial

        Other trials to consider

        Loading suggested trials...

        Top searched conditions